<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04406103</url>
  </required_header>
  <id_info>
    <org_study_id>C-046</org_study_id>
    <nct_id>NCT04406103</nct_id>
  </id_info>
  <brief_title>Direct-to-patient Health Promotion to Reduce Sedative-hypnotic Use</brief_title>
  <official_title>Direct-to-patient Health Promotion to Reduce Sedative-hypnotic Use</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>David Gardner</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of New Brunswick</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dalhousie University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dalhousie University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      New Brunswick has an aging population with Canada's highest rate of sleeping pill use. The&#xD;
      rate of long-term (chronic) use among NB seniors is 25%, well in excess of the Canadian&#xD;
      average of 10%. The rate of use is higher in women and increases with age, as do risks for&#xD;
      serious harms.&#xD;
&#xD;
      Sleeping pills risks are substantial and costly, especially to seniors. Research does not&#xD;
      support their long-term use. Risk for falls causing injuries, including hip fractures, is a&#xD;
      leading concern. They impair mental and physical functioning resulting in a loss of&#xD;
      independence and cause impaired driving and a higher rate of serious crashes. The rate of&#xD;
      near-fatal and fatal overdoses from mixing sleeping pills with other drugs is on the rise.&#xD;
      Stopping treatment can be difficult due to physical dependence and withdrawal symptoms.&#xD;
&#xD;
      Cognitive behavioural therapy for insomnia (CBTi) is recommended as the first-line treatment&#xD;
      of chronic insomnia. Sleeping pills are only to be considered when CBTi fails. However, these&#xD;
      recommendations are not reflected in primary care practice.&#xD;
&#xD;
      Internationally, many educational interventions targeting prescribers have been tried, yet&#xD;
      have failed to reduce sleeping pill use. However, a 12-page pamphlet (EMPOWER) given directly&#xD;
      to seniors in a clinical trial was associated with a large reduction in sleeping pill use.&#xD;
      Using a similarly persuasive approach, Sleepwell (mysleepwell.ca) was developed to reduce the&#xD;
      use of sleeping pills and facilitate CBTi access and use. Sleepwell differs from EMPOWER by&#xD;
      providing specific information and recommendations regarding CBTi in addition to guidance on&#xD;
      how to stop sleeping pills.&#xD;
&#xD;
      This study will evaluate the effectiveness of direct-to-patient interventions on long-term&#xD;
      sleeping pill use.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators are proposing to investigate direct-to-patient health promotion&#xD;
      interventions that promote sleeping pill dose reduction and treatment discontinuation by&#xD;
      enhancing self-efficacy through various behaviour change techniques embedded in printed&#xD;
      information provided to patients. Seniors will be invited to participate via direct telephone&#xD;
      contact, information sharing through seniors' organizations, education sessions for seniors,&#xD;
      and public notices. Prospective participants will be given the option of which way they would&#xD;
      like to participate in the research:&#xD;
&#xD;
      Option 1: full participation including baseline interview, 6-month interview, and access to&#xD;
      specific data from the participant's personal health record); Option 2: limited participation&#xD;
      to baseline and 6-month interviews only; and Option 3: limited participation to baseline&#xD;
      interview and access to specific data from the participant's personal health record.&#xD;
&#xD;
      This will form two sets of participants; those who do and those who do not permit access to&#xD;
      outcomes from their personal health record. Participants that select Options 1 or 3 will&#xD;
      consent to their medication and health resources use being assessed objectively over a six&#xD;
      month period. Participants that choose Options 1 or 2 will directly provide baseline&#xD;
      information about their health, medication use, and use of health resources via&#xD;
      communications with researchers. Similar information will be collected directly from&#xD;
      participants in this group after six months.&#xD;
&#xD;
      Random group allocation:&#xD;
&#xD;
      Options 1 and 2: i) Sleepwell package; ii) Empower package; iii) No package Option 3: i)&#xD;
      Sleepwell package; ii) No package&#xD;
&#xD;
      The investigators will compare the rates of reducing and stopping sleeping pill use among the&#xD;
      different groups over 6 months. Safety outcomes including falls and hospital visits will be&#xD;
      measured. The investigators will also track participant access to online CBTi resources using&#xD;
      Google Analytics.&#xD;
&#xD;
      Encouraging results from this study of direct-to-patient health promotion regarding insomnia&#xD;
      management and sleeping pill use can be utilized repeatedly over time to reach all&#xD;
      individuals who could benefit from the intervention, leading a transformational change in&#xD;
      insomnia management.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 6, 2020</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants discontinuing BZRA treatment within 6 months</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants discontinuing BZRA treatment within 3 months</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with BZRA dose change of 25% or more within 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>Relative change in BZRA dose between baseline and 6 months is 25% or greater.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants starting a new non-BZRA sedative-hypnotic</measure>
    <time_frame>6 months</time_frame>
    <description>Newly started on other sedative-hypnotics</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Score on the Beliefs about Medicines Questionnaire (BMQ)</measure>
    <time_frame>baseline, 6 months</time_frame>
    <description>BMQ</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of visits to mysleepwell.ca website</measure>
    <time_frame>6 months</time_frame>
    <description>The count of website visits by study participants in the Sleepwell arm during 6 months</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to fall asleep (minutes)</measure>
    <time_frame>baseline, 6 mo.</time_frame>
    <description>Sleep onset latency (SOL) measured in minutes</description>
  </other_outcome>
  <other_outcome>
    <measure>Time spent asleep (minutes)</measure>
    <time_frame>baseline, 6 months</time_frame>
    <description>Total sleep time (TST) measured in minutes</description>
  </other_outcome>
  <other_outcome>
    <measure>Sleep efficiency (%)</measure>
    <time_frame>baseline, 6 months</time_frame>
    <description>Time spent sleeping (min.) compared to total time spent in bed (min) x 100</description>
  </other_outcome>
  <other_outcome>
    <measure>Score on the Epworth Sleepiness Scale</measure>
    <time_frame>baseline, 6 months</time_frame>
    <description>Assessment of daytime sleepiness</description>
  </other_outcome>
  <other_outcome>
    <measure>Score on the Insomnia Severity Index</measure>
    <time_frame>baseline, 6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Score on the Generalized anxiety disorder - 7</measure>
    <time_frame>baseline, 6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Score on the Quality of life SF-12v2</measure>
    <time_frame>baseline, 6 mo.</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants reporting having a fall (subjective)</measure>
    <time_frame>baseline, 6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants reporting having a fall-related health visit</measure>
    <time_frame>baseline, 6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Responses to the prescriber acceptability survey</measure>
    <time_frame>6 months</time_frame>
    <description>Prescribers will be invited to respond to this end-of-study survey assessing their acceptability of the Sleepwell intervention. The development of this survey was informed by the Theoretical Framework of Acceptability</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1025</enrollment>
  <condition>Insomnia Chronic</condition>
  <arm_group>
    <arm_group_label>Sleepwell</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mailed information package includes 2 Sleepwell booklets (How to get your sleep back and How to stop sleeping pills)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Empower</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mailed information package includes 2 Empower booklets (You may be at risk AND How to get a good night's sleep without sleeping pills)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAU</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Treatment-as-usual group: no mailed intervention package.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Sleepwell</intervention_name>
    <description>Information intended to support capability, opportunity, and motivation for stopping sleeping pill use and using non-pharmacological approaches to managing insomnia.</description>
    <arm_group_label>Sleepwell</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Empower</intervention_name>
    <description>Information intended to support capability, opportunity, and motivation for stopping sleeping pill use and using non-pharmacological approaches to managing insomnia.</description>
    <arm_group_label>Empower</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  residents of New Brunswick, Canada&#xD;
&#xD;
          -  age 65 or older&#xD;
&#xD;
          -  English speaking&#xD;
&#xD;
          -  community dwelling with no anticipated change of address for the next 6 months&#xD;
&#xD;
          -  current user of BZRAs (3 or more bedtime doses in previous 7 days)&#xD;
&#xD;
          -  long-term user of BZRA: use 3 months or longer&#xD;
&#xD;
          -  BZRA indication: insomnia.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  using non-BZRA sedative-hypnotics for treating insomnia or related sleep problems&#xD;
             (e.g., trazodone, quetiapine, tricyclic antidepressant, mirtazapine, melatonin,&#xD;
             diphenhydramine, dimenhyrdinate)&#xD;
&#xD;
          -  use of alcohol or cannabis 3 or more nights a week for sleep problems&#xD;
&#xD;
          -  diagnosis of other sleep disorders: sleep terrors, sleep apnea, restless legs&#xD;
             syndrome, narcolepsy, sleepwalking&#xD;
&#xD;
          -  severe anxiety disorder&#xD;
&#xD;
          -  obsessive compulsive disorder&#xD;
&#xD;
          -  severe cognitive impairment&#xD;
&#xD;
          -  dementia&#xD;
&#xD;
          -  seizure disorder&#xD;
&#xD;
          -  spinal injury&#xD;
&#xD;
          -  chronic psychotic disorder (e.g., schizophrenia)&#xD;
&#xD;
          -  bipolar disorder&#xD;
&#xD;
          -  cancer&#xD;
&#xD;
          -  receiving palliative care&#xD;
&#xD;
          -  living in a Long Term Care facility&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David M Gardner, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dalhousie University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David M Gardner, PharmD</last_name>
    <phone>9024734955</phone>
    <email>david.gardner@dal.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of New Brunswick</name>
      <address>
        <city>Fredericton</city>
        <state>Nova Scotia</state>
        <zip>E3B 5A3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kamilla Pinter, MSc</last_name>
      <phone>18449296762</phone>
      <email>kamilla.pinter@dal.ca</email>
    </contact>
    <contact_backup>
      <last_name>Norma Chinho, BSc</last_name>
      <phone>18449296762</phone>
      <email>norma.chinho@dal.ca</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 18, 2020</study_first_submitted>
  <study_first_submitted_qc>May 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2020</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Dalhousie University</investigator_affiliation>
    <investigator_full_name>David Gardner</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>insomnia</keyword>
  <keyword>benzodiazepines</keyword>
  <keyword>deprescribing</keyword>
  <keyword>cognitive-behavioural therapy for insomnia (CBTi)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

